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Abstract
Background: Anemia is common among people living with HIV infection and is frequently associated with poor
quality of life and poor prognosis. It has been well described in antiretroviral naïve individuals and those on non-
nucleoside reverse transcriptase inhibitor-based first line antiretroviral therapy (ART) regimens. However there is
limited information on anemia for ART experienced individuals on protease inhibitor-based second line ART
regimens in resource limited settings. Our objective was to describe the prevalence and risk factors of anemia in
this ART experienced population in Malawi.
Methods: We conducted a cross-sectional study using routine facility data at two HIV clinics in Lilongwe, Malawi.
The analysis included individuals receiving protease inhibitor-based second line ART. Clinical and laboratory data
were collected at routine clinic visits. We used descriptive statistics, two-sample t-tests and multivariate logistic
regression for data analysis.
Results: Three hundred seventy-seven records were included in this analysis (37% male, median age 41 years,
median CD4 count 415 cells/μL). The prevalence of anemia was 125/377 (33.2%) −mild, moderate and severe
anemia was 17.5%, 13.8%, and 1.9% respectively. Female participants had a higher prevalence than male
participants (43.6% vs. 15.7%, p < 0.001). In multivariate logistic regression, female sex (adjusted odds ratio (aOR) 5.3;
95% CI 2.9–9.5) and a CD4 count <200 cell/ul (aOR 3.1; 95%CI 1.6–6.0) were associated with increased risk of having
anemia while a BMI ≥30 kg/m2 (aOR 0.8; 95% CI 0.6–1.0) and being on ART for more than 10 years (aOR 0.4; 95% CI
0.2–0.9) were associated with reduced risk of anemia. Being on a zidovudine- containing ART regimen was not
associated with anemia.
Conclusion: Anemia is common in people on second line ART in Lilongwe, Malawi. Screening for anemia in this
population would be a useful strategy; especially for female patients, those who are underweight and have a low
CD4 cell counts.
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Background
Anemia is common among individuals with Human Im-
munodeficiency Virus (HIV) infection [1]. Sub-Saharan
Africa has a high prevalence of people living with HIV
(PLHIV) with anemia. In these individuals anemia is asso-
ciated with malnutrition, low CD cell counts and comor-
bidities such as tuberculosis [2, 3]. Whether the person is
on ART or not, the presence of anemia predicts poor clin-
ical outcomes such as death, clinical progression to AIDS,
morbidity and a poor quality of life [4–6]. However,
individuals who recover from anemia have better clinical
outcomes [7].Therefore reducing anemia is a key compo-
nent of care in people living with HIV.
Starting antiretroviral therapy (ART) improves hemoglobin
levels and provides a protective effect against development of
new anemia [8, 9]. As a result, people on ART have lower
prevalence of anemia than those who are ART-naïve; under-
lining the value of ART in treating anemia [1, 5]. However in
resource-limited settings data on the occurrence of anemia in
PLHIV who have been on ART for several years. For PLHIV
on second line ART regimens, the prevalence and risk factors
of anemia are not well known even though persistent anemia
continues to be clinically relevant while taking ART [10, 11].
As PLHIV are now living longer and HIV/AIDS pro-
grams across sub-Saharan Africa are maturing, more
people are failing their first line ART regimens and are
requiring second line ART regimens [11]. By 2016,
approximately 1% of PLHIV (8811 PLHIV) in Malawi’s
national ART program were on second line ART regi-
mens and this number has been increasing every follow-
ing year [12]. Therefore, studies need to address the gap
in knowledge on anemia during long term ART treatment.
HIV/AIDS programs should have strategies in place to im-
prove survival and to reduce morbidity while people are
on ART including strategies to identify those people at a
greater risk of anemia during ART treatment.
We studied a cohort of ART-experienced Malawians
on second line ART to describe the prevalence of and
risk factors for anemia.
Methods
Study setting
We conducted a cross-sectional study using routine
facility data from the Lighthouse (LH) and Martin Pre-
uss Centre (MPC) HIV clinics in Lilongwe, Malawi, two
tertiary referral ART clinics. The Lighthouse Trust, oper-
ating both LH clinic and MPC, is the largest provider of
adult HIV care for PLHIV in Malawi. The integrated
TB/HIV care program and Option B+ program for HIV
positive pregnant and breastfeeding women and their
families is based at MPC, while all other services are
provided at both sites. ART regimens are standardized
in the Malawi HIV/AIDS treatment guidelines [13].
Following first line ART regimen failure, patients start a
second line ART regimen consisting of 2 NRTIs and a
PI. The PIs used are atazanavir/ritonavir (ATV/r) and
lopinavir/ritonavir (LPV/r). The NRTIs are tenofovir/
lamivudine (TDF/3TC), zidovudine/lamivudine (AZT/
3TC) and abacavir/lamivudine (ABC/3TC).
Stable individuals are seen at 3 month intervals for
routine clinic visits. At these visits, a clinical assessment
is done, tuberculosis is excluded by a 4 question symp-
tom screen and cotrimoxazole prophylaxis and antiretro-
viral treatment are supplied. Viral load monitoring is
done at 6 months following initiation of a new antiretro-
viral treatment regimen and then every 2 years thereafter
per Malawi HIV/AIDS treatment guidelines [13]. There
is no routine laboratory monitoring during ART.
Study population
Study participants were identified from the clinics’ Elec-
tronic Medical Records (EMR) system. As part of imple-
mentation of the viral load monitoring policy at
Lighthouse and Martin Preuss clinics, patients on sec-
ond line ART for at least 6 months had viral load and
safety laboratory tests. Adults (age ≥ 18 years) receiving
PI-based second line antiretroviral regimens were in-
cluded in this analysis.
Study procedures
The data covers the period between October 2013 and
April 2014. At their first routine clinic visits during this
period, the study participants had clinical evaluations done
and blood draws for full blood count (FBC), CD4 count,
liver function tests, renal function tests, and viral load.
Blood samples were processed at the UN-Project Labora-
tory in Lilongwe. VL was measured using the Abbott Real
Time HIV-1 assay system. CD4 cell counts were measured
by flow cytometry using the Becton Dickinson FACSCount
system (Becton Dickinson, Mountain View, California,
USA). FBC was analyzed in the Beckman Coulter AcT 5diff
Cap Pierce hematology analyzer (Beckman Coulter, Miami,
FL), while liver and renal function tests were analyzed in
the Roche Cobas C 311 chemistry analyzer.
The clinical evaluation and results of the laboratory tests
were recorded into the EMR that is used at clinic visits. The
EMR is used for recording clinical evaluations and for pre-
scribing and dispensing drugs. Laboratory results, demo-
graphic information, antiretroviral treatment history, weight
and height were extracted from the EMR into a database.
Variables
The WHO hemoglobin concentrations for the diagnosis
of anemia and assessment of severity were used to define
anemia as hemoglobin (Hb) <12.0 g/dl for non-pregnant
women and Hb <13.0 g/dl for men [14]. Anemia was
further classified as mild (11–11.9 g/dl in non-pregnant
women, 11–12.9 in men), moderate (8–10.9 g/dl for
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both sexes) and severe (<8 g/dl for both sexes) [14]. We
used the WHO immunological classification for estab-
lished HIV infection to classify HIV-associated immuno-
deficiency by CD4 counts: none or not significant (≥500
cells/μl), mild (350–499 cells/μl), advanced (200–349
cells/μl) and severe (<200 cells/μl) [15]. We used the
WHO definition of virologic failure to define viral sup-
pression as a viral load ≤1000 copies/ml [16]. Weight
and height measurements were used to calculate the
body mass index (BMI) which was classified as under-
weight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), over-
weight (25–29.9 kg/m2) and obese (≥30 kg/m2). Serum
creatinine, age, and sex were used to calculate the esti-
mated glomerular filtration rate (GFR) using the 4-V
MDRD eq. [17]. The mean corpuscular volumes (MCV)
and mean corpuscular hemoglobin (MCH) were classi-
fied using the local UNC Project Laboratory reference
values. The MCV and MCH were used to classify
anemia.
Statistical analysis
We used descriptive statistics to describe the population
and to obtain the prevalence of anemia. We compared
the means of the hemoglobin, age, total time on ART,
time on second line ART, BMI and GFR between those
with anemia and without anemia using two-sample t-
tests. The categorical variables sex, second line regimen,
viral load, CD4 count, MCV and RDW were analyzed
using Chi-square and Fishers exact tests. Bivariable and
multivariable logistic regression was used to estimate
odds ratios (OR) for factors associated with anemia. All
predictor variables were entered into a bidirectional
stepwise variable selection multivariate model to identify
the best set of risk factors for anemia. P-values for inclu-
sion and removal of a variable were set at 0.05 and 0.1
respectively. We used a p-value of <0.05 to test signifi-
cance and 95% confidence intervals (CI) to estimate pre-
cision. All statistical analyses were done using STATA
SE version 12.1 (College Station, Texas).
Results
Three hundred ninety-two individuals on second line
ART were enrolled in the study. 5 records were excluded
from the analysis because the individuals were not on
second line ART; they had been erroneously included
and their records showed they were not on second line
ART during data analysis. An additional 10 records were
excluded because the age was less than 18 as per inclu-
sion criteria for this analysis. Therefore 377 records were
included in the analyses.
Approximately two-thirds (237/377) of the study partici-
pants were female (Table 1). This is consistent with the ra-
tio of men/women in the study clinic so women are not
overrepresented. The average age of the participants was
41.9 years (SD = 9.6). More than three quarters of the par-
ticipants (289/377) had been receiving ART for more than
5 years; the mean duration of ART use was 7.4 years
(SD = 2.8). Anemic participants were significantly younger
(40.5 years vs. 42.6 years, p-value = 0.01) and had been on
second line ART for a shorter duration (2.9 years vs.
3.7 years, p-value = 0.004) than the non-anemic partici-
pants. There were no pregnant women.
The distribution of hemoglobin values between male
and female participants is shown in Fig. 1. Men had
higher hemoglobin values (median of 14.5 mg/dl; inter-
quartile range (IQR) 13.6–15.5 mg/dl) than women (me-
dian of 12.3 mg/dl; IQR 11.1–13.1 mg/dl).
The prevalence of anemia was 125/377 (33.2%). Fe-
male participants had a higher prevalence than male
participants (43.6% vs. 15.7%, p < 0.001). There were
no differences in the total time on ART, time on
second line ART and participants with suspected
virologic failure on second line ART between male
and female participants (data not shown).
Table 1 Characteristics of HIV-infected patients on second line
ART in two urban HIV clinics in Lilongwe, Malawi, means ±SD or
n (%)
Characteristic Anemic Not anemic P-value†
n = 125a n = 252a
Sex (%)
Male 22 (17.6) 118 (46.8) <0.001
Female 103 (82.4) 134 (53.2)
Age, mean (SD) years 40.5 (9.4) 42.6 (9.6) 0.01
Total time on ART, mean
(SD) years
7.1 (2.5) 7.5 (3.0) 0.17
Time on second line ART,
mean (SD) years
2.9 (2.0) 3.7 (2.4) 0.004
Second line regimen (%)
Contains AZTb 19 (15.2) 48 (19.1) 0.37
Does not contain AZT 106 (84.8) 204 (81.0)
CD4 count (×103cells/ul)
> 500 42 (35.0) 89 (35.7) 0.003
350–499 30 (24.0) 72 (28.9)
200–349 23 (18.4) 61 (24.5)
< 200 30 (24.0) 27 (10.8)
Viral suppression (copies/ml)
< =1000 110 (89.4) 230 (91.6) 0.365
> 1000 13 (10.6) 21 (8.4)
Body mass index, mean (SD) kg/m2 24.2 (5.1) 25.1 (5.2) 0.17
Estimated glomerular filtration rate 91.5 (31.0) 91.8 (29.9) 0.17
Anemia defined as Hb <12.0 g/dl for non-pregnant women and Hb <13.0 g/dl
for men
aMissing values not included in the totals
bAZT- zidovudine
†p-value for t-test or chi-squared test as appropriate
Ngongondo et al. BMC Infectious Diseases  (2018) 18:39 Page 3 of 8
The prevalence of mild, moderate and severe anemia
was 66/377 (17.5%), 55/377 (13.8%) and 7/377 (1.9%) re-
spectively. Among people who had anemia, most of the
cases had normocytic (87/125) and normochromic (98/
125) anemia (Table 2). A few cases had microcytosis (13/
125) and macrocytosis (25/125). All 7 cases with severe
anemia were female; 6 of these cases had microcytic,
hypochromic anemia while 1 case had normocytic, nor-
mochromic anemia. 48/52 cases with moderate anemia
were female participants while only 4 cases with moder-
ate anemia were male participants. Most men with
anemia (18/22 of men with anemia) had mild anemia.
During multivariate logistic regression female sex
(adjusted odds ratio (aOR) = 4.1; 95% CI 2.5–7.0) and a
CD4 count <200 cell/ul (aOR = 2.4; 95% CI 1.3–4.4)
were associated with increased risk of having anemia
while being on ART for more than 10 years (aOR = 0.4;
95% CI 0.2–0.8) and having a BMI ≥ 30 kg/m2 were as-
sociated with a reduced risk of anemia (Table 3). Age,
viral suppression, glomerular filtration rate and the pres-
ence of AZT in the current regimen were not associated
with anemia.
Discussion
We found that anemia was common in this cohort on
second line ART. The prevalence was highest in women
who also had lower hemoglobin values and more severe
degrees of anemia. Being female and a CD4 count <200
cell/ul were risk factors for anemia while BMI ≥30 kg/
m2 and being on ART for more than 10 years were asso-
ciated with reduced risk of anemia.
Although ART use is associated with a decrease in the
prevalence of anemia, the prevalence in our study popu-
lation was high [1, 8, 18]. Among the general adult
population in Malawi, the prevalence of anemia ranges
from 17% in men to 28% in non-pregnant women [19,
20]. Compared to this, we report a higher prevalence of
33.2% in people on second line ART− 15.7% in men and
43.6% in women. The prevalence of anemia in this study
is similar to the prevalence observed in people on first
line ART regimens where it was reported at 38.2% in a
study of people on first line ART regimens [21]. How-
ever this prevalence is lower than the prevalence in ART
naïve individuals which was reported at 77.4% in one
study [22]. This is consistent with studies that show that
ART reduces the prevalence of anemia in people living
with HIV [21, 22].
The high prevalence of anemia in our study population
is still worrying and points to a larger problem— that
anemia remains untreated in large numbers of people on
ART. This is a concern because anemia lowers the qual-
ity of life, an important treatment goal while on ART,
and increases the risk of progression to AIDS and death
Table 2 Description of the type and severity of anemia, n = 125
Mild Moderate Severe P-value†
(N = 66) (N = 52) (N = 7)
sex 0.002
Male 18 (27.3) 4 (7.7) 0 (0.0)
Female 48 (72.7) 48 (92.3) 7 (100)
MCV <0.001
<71 1 (1.5) 6 (11.5) 6 (85.7)
71–95 51 (77.3) 35 (67.3) 1 (14.3)
>95 14 (21.2) 11 (21.2) 0 (0.0)
MCH <0.001
<23 0 (0.0) 9 (17.3) 6 (85.7)
23–34 62 (93.9) 35 (75.0) 1 (14.3)
>34 4 (6.1) 4 (7.7) 0 (0.0)
MCV− mean corpuscular volume
MCH− mean corpuscular hemoglobin
†p-value for chi-squared test
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Fig. 1 Distribution of hemoglobin among HIV infected patients on second line ART in male and female participants at 2 urban HIV clinics in
Lilongwe, Malawi
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[4–6]. The high prevalence of anemia highlights the
need to address causes of anemia in people on ART.
The mechanism of anemia in this study population as
in other populations living with HIV is multifactorial
and includes both HIV-related and non-HIV related
causes. The HIV-related causes are HIV itself which
causes anemia of chronic disease due to chronic inflam-
mation; opportunistic infections such as mycobacteria
and fungi and neoplasms such as lymphoma which infil-
trate bone marrow and inhibit maturation of progenitor
cells as well as medications used during treatment of
HIV and associated conditions such as zidovudine and
cotrimoxazole [3, 7]. Treating HIV-related anemia
should be with effective ART; appropriate treatment for
the opportunistic conditions and removal of any sus-
pected medications [1, 7, 23]. In our study, a few anemic
participants (13/377) had VL >1000 cps/ml and were
suspected to have treatment failure while the rest of the
participants had viral suppression. We did not have data
on current and past medical history and drug history
(other than the ART history). However since this was a
very ART experienced cohort, it is possible that
Table 3 Factors associated with anemia in HIV-infected patients on second line ART at two urban HIV clinics in Lilongwe, Malawi
Unadjusted Odds Ratios Adjusted Odds Ratios
Characteristic (95% CI) p-value (95% CI) p-value
Sex
Male 1 1 1
Female 4.1 (2.5–7.0) <0.001 5.3 (2.9–9.5) <0.001
Age
≤29 1
30–39 1.4 (0.6–3.2) 0.39
40–49 0.9 (0.4–1.9) 0.69
≥50 0.6 (0.3–1.5) 0.30
Total time on ART (years)
0–5 1 1 1
6–10 1.2 (0.7–2.0) 0.60
11–15 0.4 (0.2–0.8) 0.02 0.4 (0.2–0.9) 0.02
Second line ART regimen
contains AZT 1
does not contain AZT 1.3 (0.7–2.4) 0.36
CD4 cell count
≥500 1 1 1
350–499 0.8 (0.5–1.6) 0.67
200–349 0.8 (0.4–1.5) 0.47
<200 2.4 (1.3–4.4) 0.01 3.1(1.6–6.0) 0.001
Viral load
<=1000 1
>1000 1.3 (0.6–2.7) 0.49
Body mass index
<18.5 1.5 (0.7–3.5) 0.33
18.5–24.9 1 1 1
25–29.9 1.0 (0.6–1.8) 0.86
≥30 0.6 (0.3–1.1) 0.08 0.8 (0.6–1.0) 0.02
Glomerular filtration rate
>90 1
30–89 0.7 (0.5–1.1) 0.15
<30 9.0 (1–78.4) 0.047
CI-confidence intervals
AZT- zidovudine
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participants had a significant history of opportunistic
conditions and drugs that can cause anemia.
Endemic causes of anemia play a role in both the
general population and in people living with HIV. In
sub-Saharan Africa, these are chronic malnutrition; nu-
tritional deficiencies such as iron deficiency, vitamin B12
deficiency and folate deficiency; infections and parasite
infestations such as malaria, schistosomiasis and hook-
worms; pregnancy and hemoglobin disorders such as
thalassemia, other hemoglobinopathies and other rare
congenital hematologic disorders [24–26]. In settings
such as ours where the anemia prevalence is already
high from endemic causes, HIV infection worsens pre-
existing anemia through its effects of chronic inflamma-
tion and immunosuppression [27].
Despite iron deficiency being a common cause of
anemia within African populations, there was no pre-
ponderance of microcytosis nor hypochromia in our
study population to suggest that iron deficiency is an im-
portant cause of anemia in the study participants [].
Other studies have reported high rates of iron deficiency
in people living with HIV and in those on ART [26]. A
possible reason for the low prevalence of iron deficiency
anemia in our study population is that this was an urban
population which is associatied with lower prevalence of
iron deficiency that rural populations [25]. In addition,
the study participants were continuously in care at the
HIV clinics with access to clinical assessments and
hemoglobin level checks. The participants had many op-
portunities to be diagnosed with anemia and to have iron
supplementation. The WHO recommends presumptive
iron supplementation, anti-helminthic and anti-malarial
therapy to treat anemia in resource limited settings where
large workloads for health workers and inadequate labora-
tory capabilities make diagnosing specific causes of
anemia difficult [28]. This approach is recommended in
the Malawi Standard Treatment Guidelines and in other
African countries [29]. However, a study in Mozambique
showed that there is need for additional efforts to find and
treat specific causes of anemia in PLHIV including in
those on ART [30].
Nearly half of the female participants in this study had
anemia, consistent with studies that show high preva-
lence of anemia in women living with HIV. Women liv-
ing HIV are at a higher risk of severe anemia than men
[4, 30]. The high prevalence in the women also reflects
an overall higher prevalence of anemia in women in the
general population [2]. In addition, six out of the seven
women that had severe anemia in this study had micro-
cytosis that indicates iron deficiency anemia − all were
given iron supplementation. In contrast, almost all men
had mild anemia except for 4 cases with moderate
anemia. Whether additional factors such as differential
ART failure in women, contribution of anemia in failure
of first line ART regimen or use of NNRTI for preven-
tion of mother to child transmission (PMTCT) may have
contributed to the high prevalence of anemia in women
this study is not known. Women could benefit from
routine screening for anemia before starting ART and
routine hemoglobin monitoring while they are on ART.
There are several reasons for the high proportion of
women in our study population. In Malawi, more
women are infected with HIV than men; women tend to
present for health services more frequently than men
[20] and with the Option B+ program that has been im-
plemented since 2011, pregnant women are systematic-
ally targeted for HIV testing and those who have HIV
start life-long ART regardless of the CD4 cell count [13].
As a result, more women are on ART than men. Our
study population has similar gender demographics with
the overall clinic population so that women are not over-
represented in the study population. From our findings,
there was no difference in time spent on first line ART,
time on second line ART and in virologic suppression
between men and women.
We did not see an association between AZT in the
current second line ART regimen and anemia in our ana-
lysis. This is in contrast with the widely recognized risk of
anemia reported in association with AZT use [4, 31, 32].
We suspect that the lack of an association was because
participants who would have been anemic at initiation of
ART were not started on an AZT-based ART regimen
and those that were suspected of having AZT associated
anemia would have already been switched from AZT be-
fore these data were collected. Huffam et al. also reported
that prior ART experience could be protective against
subsequent development of AZT associated anemia in
later regimens [33]. This is relevant to this study popula-
tion that had significant prior ART experience. Partici-
pants in this study spent an average of 7.4 years on ART.
In addition, some studies have reported that AZT is not a
significant risk factor for anemia when it is used as part of
a combinational ART regimen as is the case in our study
population [21, 29].
In this study, we described anemia in among an ART-
experienced cohort on PI-based second line ART. A
strength of this analysis is that it was conducted on a
well-characterized cohort that is generalizable because it
used data collected during routine clinic visits.
An important limitation of the study is the lack of data
on other known risk factors for anemia such as the pres-
ence of fever, opportunistic infections (e.g. TB, oral can-
didiasis) and concurrent use of other medication which
were not measured and were not included in the analysis
[27]. When analyzing the data on AZT, we were not able
to look at substitutions that were made prior to the date
of sample collection. This could have the effect of con-
founding by indication the significance of AZT in the
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ART regimens. Because Hb monitoring is not routinely
done for patients on ART outside of the two facilities in-
cluded in this study, the prevalence reported may be dif-
ferent than that in the wider HIV-infected population on
second line ART.
Conclusion
The study shows that anemia is present at a high preva-
lence in ART experienced people on second line ART
regimens. The study further shows the need to identify
and treat the causes of anemia in addition to giving
them ART. As would be expected, female patients, those
with CD4 cell count less than 200cells/ul were at higher
risk of anemia while those who were overweight had
lower risk of anemia. Further longitudinal follow-up
studies are needed to explore long term hemoglobin
changes after antiretroviral treatment is initiated and to
find the specific causes of anemia in people on ART.
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